Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19

Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19

<p dir="ltr">The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CM...

Full description

Saved in:
Bibliographic Details
Main Author: Mohamad Y. Khatib (11659459) (author)
Other Authors: Karimulla S. Shaik (14777197) (author), Amna A. Ahmed (14777200) (author), Mohammad A. Alwraidat (14777203) (author), Ahmed S. Mohamed (11659456) (author), Mohamad R. Abou Kamar (14777206) (author), Mouhammad Z. Sharaf Eldean (14777209) (author), Bashar K. Aldaraiseh (14777212) (author), Abdulqadir J. Nashwan (11659453) (author)
Published: 2020
Subjects:
Biomedical and clinical sciences
Clinical sciences
Immunology
CMV reactivation
Gastrointestinal bleeding
Intestinal perforation
Tocilizumab
Immunosuppressive therapy
COVID-19
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items